Placebo twice daily

DRUG4 trials

Sponsors

Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Dr. Reddy's Laboratories Limited

Conditions

Actinic Keratosis (AK)Acute Coronary SyndromeAnkle InjuriesAsthma

Phase 2

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

CompletedNCT01311661

Boehringer IngelheimAsthma

Start: 2011-03-31Updated: 2014-05-01

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

CompletedNCT03116698

Dr. Reddy's Laboratories LimitedActinic Keratosis (AK)

Start: 2017-02-14End: 2018-07-05Updated: 2019-04-24

Phase 3

5% Topical Ibuprofen (IBU) for Ankle Sprain

CompletedNCT01945034

PfizerAnkle Injuries

Start: 2013-11-30End: 2015-02-28Updated: 2016-05-26

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

CompletedNCT02145468

GlaxoSmithKlineAcute Coronary Syndrome

Start: 2014-06-03End: 2015-12-14Updated: 2017-06-02

Related Papers

Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial.

2021-09-0810 citations

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction

JAMA2016-04-04237 citations

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

Respiratory Research2015-08-1713 citations

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.

2015-07-167 citations